A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

NCT00042679 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Pulmonary Neoplasms
Neoplasms, Lung

Interventions

DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: LY900003

Sponsor

Eli Lilly and Company